Reviewing Outlook Therapeutics (NASDAQ:OTLK) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Outlook Therapeutics (NASDAQ:OTLK) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Outlook Therapeutics and Mosaic ImmunoEngineering’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98 million	($11.41)	-0.63
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.13)	-7.92

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.2% of Outlook Therapeutics shares are held by institutional investors. 3.4% of Outlook Therapeutics shares are held by company insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Outlook Therapeutics and Mosaic ImmunoEngineering, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0	1	7	0	2.88
Mosaic ImmunoEngineering	0	0	0	0	N/A

Outlook Therapeutics currently has a consensus price target of $45.55, indicating a potential upside of 536.17%. Given Outlook Therapeutics’ higher probable upside, analysts plainly believe Outlook Therapeutics is more favorable than Mosaic ImmunoEngineering.

Profitability

This table compares Outlook Therapeutics and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	N/A	-170.94%
Mosaic ImmunoEngineering	N/A	N/A	-667.24%

Volatility and Risk

Outlook Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Summary

Outlook Therapeutics beats Mosaic ImmunoEngineering on 6 of the 9 factors compared between the two stocks.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.